| Course | HCR 576 Drug Discovery, Development and Regulations |
|---|---|
| Module | Module 7 |
| Paper type | Regulatory comparison table |
| Length | About 579 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 576 Module 7
FDA and EMA Side by Side: A Comparison Table of U.S. and EU Drug Regulation
Student Name
MS in Regulatory Science, Arizona State University
HCR 576: Drug Discovery, Development and Regulations
Instructor Name
Month Day, Year
FDA and EMA Side by Side: A Comparison Table of U.S. and EU Drug Regulation
Introduction
The United States and the European Union are the two largest markets for new medicines, and most sponsors plan to file in both. Their systems share scientific standards through international guidelines but differ in structure, procedure and timing. The table below compares them across twelve areas, drawing on a published comparison of approval processes and the regulators' own frameworks (Van Norman, 2016).
Comparison Table
| Area | United States (FDA) | European Union (EMA and member states) |
|---|---|---|
| Structure | One federal agency decides | EMA's scientific committee gives an opinion; the European Commission grants authorization |
| Legal basis | Federal Food, Drug, and Cosmetic Act; 21 C.F.R. | EU directives and regulations, including the Clinical Trials Regulation |
| Starting trials | IND filed; may begin after 30 days unless placed on hold | Clinical trial application through a single EU portal, assessed by member states under the Clinical Trials Regulation |
| Ethics review | Institutional review board at each site or a single IRB | Ethics committee opinion within each member state's assessment |
| Marketing application | New Drug Application or Biologics License Application | Marketing authorization application, centralized for many product types |
| Standard review time | 10 months from filing for a standard review | 210 active days for the committee opinion, plus clock stops and Commission decision |
| Expedited programs | Fast track, breakthrough, accelerated approval, priority review | PRIME, accelerated assessment, conditional marketing authorization |
| Pediatric requirements | Pediatric study plan under the Pediatric Research Equity Act | Pediatric investigation plan agreed early with the Pediatric Committee |
| Orphan incentives | Seven years of exclusivity, tax credits, fee waivers | Ten years of market exclusivity, protocol assistance, fee reductions |
| GMP inspection | FDA inspects domestic and foreign sites | Member state authorities inspect; mutual recognition agreement with FDA for many inspections |
| Pharmacovigilance | Adverse event reporting; REMS when needed | Risk management plan required with every application; pharmacovigilance committee |
| Transparency | Approval packages and advisory committee materials published | Public assessment reports and clinical data publication policy |
Commentary
Convergence
In the United States, trials start under the IND rules (21 C.F.R. § 312.20); in the EU, under the Clinical Trials Regulation (European Parliament & Council of the European Union, 2014). Both regions build on the same ICH guidelines for quality, safety, efficacy and good clinical practice, so a well-designed development program can support both applications. The mutual recognition agreement on GMP inspections means the agencies increasingly rely on each other's inspections of manufacturing sites.
Differences That Matter for a Sponsor
The biggest practical differences are procedural. The EU requires a pediatric investigation plan to be agreed much earlier than the U.S. pediatric study plan, which can shape early development. Review timelines differ in how the clock runs, so a sponsor planning launch dates must model both. Expedited programs do not map one-to-one: a drug with U.S. breakthrough designation may or may not qualify for PRIME. And the EU's risk management plan is required for every new product, while a U.S. REMS is imposed only when needed.
Strategy
A sponsor targeting both markets should hold early scientific advice meetings with both regulators, align the pediatric plans, design phase 3 trials that meet both regions' expectations for comparators and populations and prepare a single Common Technical Document that can be adapted for each submission.
Conclusion
The FDA and EMA regulate medicines to the same scientific standards through different institutions and procedures. Comparing them side by side shows where a single development program can serve both and where a sponsor must plan for differences from the start.
References
European Parliament & Council of the European Union. (2014). Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use. Official Journal of the European Union, L 158, 1-76.
Requirement for an IND, 21 C.F.R. § 312.20 (2025).
Van Norman, G. A. (2016). Drugs and devices: Comparison of European and U.S. approval processes. JACC: Basic to Translational Science, 1(5), 399-412. https://doi.org/10.1016/j.jacbts.2016.06.003
Reading the HCR 576 Module 7 assignment instructions
HCR 576 ends with the EU drug development process, regulatory framework and submission in Week 7, and Paper 3 is a comparison of the U.S. and EU regulatory frameworks prepared as a table or spreadsheet. The syllabus suggests areas such as GMP manufacturing, the IND and clinical trial regulations, and the week's readings include Van Norman's comparison of European and U.S. approval processes and EMA's overview of the European regulatory system. Rows should be things both systems regulate, so each row compares like with like, and cells should be phrases, not paragraphs. A brief commentary after the table, on where the systems converge and where a sponsor must plan for differences, turns the table into analysis. As the third paper, it completes the share of the grade, 22.5%, set aside for individual papers.
Inside the HCR 576 Module 7 example
The sample opens with two sentences on why the comparison matters to sponsors and names its main source. The core is a twelve-row table comparing FDA and EU regulation across structure, legal basis, starting trials, ethics review, marketing applications, review times, expedited programs, pediatric requirements, orphan incentives, GMP inspection, pharmacovigilance and transparency, each cell a short phrase. A commentary follows under three headings: convergence through shared guidelines, differences that matter in practice and a short strategy for a sponsor filing in both regions. The conclusion sums up the comparison briefly, and the table's margin note gives the reason for one-phrase cells.
Reading the HCR 576 Module 7 grading rubric
Paper 3 is scored as one of the course's three papers. Credit goes to a table that covers the areas the syllabus suggests and others relevant to development, accurate entries for both regions, rows that compare equivalent features, concise cells and a commentary that explains what the differences mean. Points are lost when entries are wrong or outdated, such as ignoring the EU Clinical Trials Regulation, when rows mix unrelated features, when cells contain paragraphs and when the table stands alone with no analysis. Readers value accuracy on timelines and expedited programs, since those are where sponsors most often misjudge the two systems. A table with a short but careful commentary usually scores higher than a long essay with a weak table.
HCR 576 Module 7 help with common mistakes
List the areas first, then fill both columns for each before moving on. Check entries against the regulators' own websites and the assigned comparison article. Keep cells to short phrases. Include the EU Clinical Trials Regulation and the pediatric investigation plan, which differ most from U.S. practice. Add a short commentary on convergence, key differences and strategy. If you are unsure whether an entry is current, the desk can help you check it. Date your table, since both systems change; the EU's pharmaceutical legislation in particular is being revised. Cite the regulations or guidance behind your entries in the commentary so a reader can follow up on any row.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 576 and MS in Regulatory Science sample papers
- HCR 576 Module 1: Paper: Product Profile for a Drug Under Development
- HCR 576 Module 5: Paper: A Recent Drug Recall and the FDA Process
- HCR 564 Module 4: Paper 1: Critique of Future Developments in Global Therapeutics
- HCR 579 Module 4: Written Assignment 3: Dissecting a Phase 0 Study
- HCR 543 Module 7: Summative Evaluation Paper: Emerging Food Safety Issues
- HCR 555 Module 6: Assignment 5: A Pharmacogenomic Risk-Minimization Plan
HCR 576 Module 7 questions, answered
Where can I find a free HCR 576 Module 7 sample paper?
The page above has the full comparison table of FDA and EU drug regulation with commentary.
What is the EU equivalent of an IND?
A clinical trial application submitted through the EU portal under the Clinical Trials Regulation.
Who approves new medicines in the EU?
EMA's committee gives a scientific opinion and the European Commission grants the marketing authorization.
What is a pediatric investigation plan?
An EU plan for pediatric studies agreed early with EMA's Pediatric Committee, required before most marketing applications.
How long is orphan exclusivity in the US and EU?
Seven years in the United States and ten years in the European Union.